Novartis | NOVN - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
AbbVie USD 10.27B 538M 2026-03
Alcon AG USD 2.41B 4M 2026-03
Almirall EUR 517.4M 32K 2025-12
Amgen USD 4.78B 1.12B 2026-03
AstraZeneca USD 8.18B 4.35B 2026-03
Autolus Therapeutics Ltd USD 85.73M 11.02M 2026-03
Bayer EUR 9.88B 452M 2026-03
Biogen USD 1.96B 69.6M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Eli Lilly USD 10.02B 285M 2026-03
Fresenius EUR 5.25B 337M 2025-12
Fresenius Medical Care EUR 4.34B 63M 2026-03
Genmab DKK 798M 235M 2025-12
Gilead Sciences USD 23.52B 18.55B 2026-03
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
GRIFOLS EUR 1.45B 255.28M 2026-03
Hikma Pharmaceutical USD 1.34B 702M 2025-12
J&J USD 17.44B 1.53B 2026-03
Lakefront Biotherapeutics EUR 70.18M 50.08M 2026-03
Lonza CHF 2.9B 184M 2025-06
Merck EUR 4.09B 687M 2026-03
Merck USD 18.17B 8.01B 2026-03
Novartis USD 9.29B 507M 2026-03
Novartis USD 9.8B 23M 2025-12
Novo Nordisk DKK 37.21B 9.56B 2026-03
Orion EUR 302.9M 64.2M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
Philips EUR 3.6B 775M 2026-03
Recordati EUR 482.31M 98.3M 2026-03
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sanofi EUR 9.31B 1.2B 2026-03
UCB EUR 2.96B 196M 2025-12